Delivery Method:
Overnight Delivery
Recipient:
Kratom Spot

16755 Von Karman Artery
Irvine, CA 92606
United states

Issuing Role:
Center for Drug Evaluation and Research

United states

Black HHS-Blue FDA Logo

10903 New Hampshire Avenue
Silver Spring, Dr. 20993

May 18, 2018

Alarm LETTER

VIA OVERNIGHT DELIVERY

RETURN RECEIPT REQUESTED

Kratom Spot

16755 Von Karman Avenue

Irvine, CA 92606

This is to advise yous that the U.Due south. Food and Drug Assistants (FDA) reviewed your website at the Internet address world wide web.kratomspot.com in April 2018 and has adamant that you lot have orders in that location for diverse kratom products, including but not limited to, "Red Thai Kratom Powder," "Green Thai Kratom Powder," "Indo White Vein Kratom Powder," "Bali White Vein Kratom Powder," "White Vein Sumatra Kratom Powder," "Indo Green Vein Kratom Pulverization,"  "Borneo White Vein Kratom Powder," "Ruddy Vein Indo Kratom Powder," "Green Malay Kratom Powder," "Sumatra Red Vein Kratom Powder," "Bali Red Vein Kratom Powder," "Red Thai Kratom Capsules," "Ultimate White Vein Kalimantan Kratom Capsules," "Maeng Da Kratom Powder," "Green Malay Kratom Capsules," "White Maeng Da Kratom Powder," "Crimson Maeng Da Kratom Powder," "Super Dark-green Indo Kratom Capsules," "Sumatra Red Vein Kratom Capsules," "Red Vein Malay Kratom Capsules," "Indo White Vein Kratom Capsules," "Maeng Da Kratom Capsules," "Ultra Enhanced Malay Kratom Pulverisation," "Ultra Enhanced Bali Kratom Pulverisation," "Ultra Enhanced Borneo Kratom Pulverisation," "Ultra Enhanced Indo Kratom Powder," "Ultra Enhanced Sumatra Kratom Pulverization," "Kratom Extract 8x Kratom Powder," and "Ultra Enhanced Maeng Da Kratom Powder." Nosotros have as well reviewed your social media websites at www.facebook.com/kratomspotonline.com and www.twitter.com/kratomspot.  FDA has determined that these products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 UsaC. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. 352. You can find the FD&C Act and FDA regulations through links on FDA's habitation page at www.fda.gov.

On Oct 26, 2017, the Acting Secretary of the Section of Health and Human Services, under department 319 of the Public Health Service Act, 42 U.S.C. 274d, determined that a public health emergency exists nationwide involving the opioid crisis. As described in more detail below, you market place various kratom products for, among other things, the treatment or cure of opioid addiction and withdrawal symptoms. Withal, these products have not been determined past FDA to be safe and effective for these (or any other) uses. Further, the unproven treatments could crusade patients to forego or filibuster FDA-approved treatments for opioid habit and withdrawal. The marketing and auction of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, merits to diagnose, mitigate, preclude, treat or cure opioid addiction.

Unapproved New Drugs and Misbranded Drugs

The claims on your website and social media sites establish that the to a higher place-mentioned products are drugs as defined by department 201(g)(one)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of affliction. Every bit explained farther below, introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act.

Examples of labeling claims observed on your website, www.kratomspot.com , that establish the intended apply of your products include, but may not be limited to, the following:

On the page of your website titled "Web log: The Opioid Epidemic and the Kratom Possible Solution: How Can Kratom assist The Opioid Crisis?":

  • "[Kratom] has natural pain relief properties and has been shown to be safe for use. Kratom offers people who suffer from chronic pain an pick to synthetic drugs altogether."
  • "Many of our customers have reported that kratom has helped them quit the use of heroin and synthetic drugs. The mood tiptop qualities of kratom reduces opiate withdrawal effects."
  • "A quick look at our product reviews reveals hundreds of testimonials on how this amazing herb helped people boot addiction and thwart pain."

On the folio of your website titled "Blog: How to Quit Opiate Drugs with Kratom?":

  • "Are you i of those who is swell on stopping opiate drugs? Well, nosotros accept an excellent solution for your trouble. The reply is herbal solution – Kratom plant, besides known equally Mitragyna speciosa."
  • "The all-time kratom to quit opiate drugs is Archetype Reddish Bali, also known every bit Blood-red Indo Kratom. Information technology is a powerful sedative and painkiller. Therefore, information technology is all the more advantageous in fighting against opiate addiction."
  • "The Red Vein type of Kratom is more than desirable to use to quit opiates because it can relieve the withdrawal symptoms well. It is a healthy and natural way to overcome opiate drug addiction. Whether you are a victim of heroin addiction or addicted to oxycodone, hydrocodone, suboxone, or methadone, Kratom tin successfully eliminate opiate withdrawal symptoms for you."
  • "Mitragynine has considerable effect in controlling opiate addiction."
  • "How I overcame Methadone addiction with Kratom? . . . If y'all wish to break free from the clutches opiate addiction, yous should try out Kratom . . . Purchase Kratom correct away and pave your way to deaddiction through this South E Asian wonder constitute."

On the page of your website titled "Blog: Which types of Kratom are used for opiate withdrawal?":

  • "Information technology has been known for quite some while now that Kratom is useful in the withdrawal from opiate addiction."
  • "It helps in reduction of indisposition and pain associated with withdrawal. Also, it uplifts mood and acts like an anxiolytic. With the right dose, it too helps in relieving symptoms like nausea and vomiting."
  • "Types of Kratom used for opiate withdrawal. Since there are many strains and subspecies of Kratom, with various functions associated with the active ingredient, we tin use unlike strains in the management of the various symptoms of withdrawal . . . Bali Blend – Bali red vein and 8x extract from Kratom Spot. It is the best Kratom for Opiate withdrawal . . . Sumatra Crimson Vein Powder. This strain of Kratom is well-nigh useful for the removal of opiate cravings . . . Greenish Thai Powder . . . Patients suffering from decreased libido or sexual dysfunction due to opiate withdrawal can accept this strain and its effects last for up to 8 hours."
  • "Dose of Kratom for opiate withdrawal. At lower doses, Kratom affects the delta receptors, just at college doses, it acts on the mu opioid receptors . . .."

In improver to claims on your website, claims observed on your social media sites that establish the intended utilise of your products include, but may not be limited to, the post-obit:

https://www.facebook.com/kratomspotonline:

  • "Kratom Spot October 26, 2017. The federal government merely declared the opioid crisis a public wellness emergency. Positive news for kratom as a result. Kratom is an all natural culling..."

The claims on your website and social media sites constitute that your kratom products are drugs under section 201(1000)(1)(B) of the FD&C Act, 21 U.S.C. 321(one thousand)(i)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of affliction—in detail, for opiate withdrawal and addiction.

Your kratom products are also "new drugs" nether section 201(p) of the FD&C Human activity, 21 United statesC. 321(p), because they are not mostly recognized as safe and constructive for use under the conditions prescribed, recommended, or suggested in their labeling. Under department 505(a) of the FD&C Human activity, 21 The statesC. 355(a), new drugs may non be introduced or delivered for introduction into interstate commerce without prior approving from FDA. No approved application pursuant to section 505 of the FD&C Human activity, 21 U.Due south.C. 355(a), is in issue for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.Southward.C. 331(d) and 355(a).

Section 503(b)(1) of the FD&C Human action, 21 U.s.a.C. 353(b)(i), identifies criteria for determining the prescription status of a production. Your above-mentioned kratom products are prescription drugs as defined in section 503(b)(ane)(A) of the FD&C Act, 21 U.South.C. 353(b)(one)(A), because in light of their toxicity or other potentiality for harmful effect, or the method of their use, or the collateral measures necessary to their utilise, they are non safe for use except under the supervision of a practitioner licensed by law to administer such drugs.

Your in a higher place-mentioned kratom products are intended for the handling or cure of opioid addiction and withdrawal symptoms, and/or other conditions that are not amenable to cocky-diagnosis or treatment without the supervision of a licensed practitioner. A drug is misbranded undersection 502(f)(ane) of the FD&C Act, 21 U.S.C. 352(f)(i), if the drug fails to bear adequate directions for its intended use(s). "Adequate directions for apply" is defined in 21 CFR 201.5 equally "directions nether which the layman can employ a drug safely and for the purposes for which it is intended."  Because the conditions for which your above-mentioned kratom products are intended require the supervision of a practitioner licensed by law to administer such drugs, acceptable directions cannot be written and then that a layperson can apply your products safely. Thus, your kratom products' labeling fails to bear adequate directions for their intended uses, which causes the products to be misbranded under section 502(f)(1) of the FD&C Act, 21 The statesC. 352(f)(1). The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates department 301(a) of the FD&C Act, 21 U.S.C. 331(a).

The violations cited in this letter are not intended to be an spread-out statement of violations that exist in connection with your marketed products. Yous are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.

You should accept prompt action to correct the violations cited in this letter. Failure to promptly correct these violations may issue in legal activeness without further notice, including, without limitation, seizure and injunction.

Within fifteen (15) working days of receipt of this letter, delight notify this office in writing of the specific steps you have taken to right violations. Include an explanation of each pace existence taken to forbid the recurrence of violations, equally well as copies of related documentation. If you believe that your products are non in violation of the FD & C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective activity within fifteen working days, country the reason for the delay and the fourth dimension within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance, 10903 New Hampshire Avenue, WO51, Silverish Jump, Medico 20993-0002 or by email to FDAADVISORY@fda.hhs.gov.

Sincerely,

/Southward/

Donald D. Ashley

Director

Role of Compliance

Eye for Drug Evaluation and Research

Food and Drug Assistants

Cc:

Cafete, Inc.

Atef Aresheh, President

500 Due north. State College Boulevard, Suite 100

Orangish, CA 92868

Kratom Spot

204 Technology Drive

Irvine, CA 92618

Kratom Spot

1800 E. McFadden Avenue, Suite 200

Santa Ana, CA 92705